We are a few years away from bringing back the WOOLLY MAMMOTH, says Colossal Biosciences founder

• Colossal Biosciences successfully de-extincted dire wolves, extinct for 12,500 years, using ancient DNA and cloning.
• The company's flagship project is the woolly mammoth, with first calves expected in a few years, utilizing over 100 mammoth genomes.
• Colossal Biosciences has attracted notable investors and is reportedly valued at $200-$300 billion, having also spun off unicorn companies like Astromek.
• The technologies developed for de-extinction, such as AI, computational biology, genetic engineering, and developmental biology, have direct applications to human healthcare.

Colossal Biosciences founder Ben Lamm discusses his company's pioneering work in de-extinction, including the successful reintroduction of dire wolves and ongoing efforts with woolly mammoths. He highlights the advanced genetic engineering and AI technologies developed, their significant valuation, and the broader applications of these innovations to human healthcare and conservation.